GSK agrees $5.1bn price for cancer drug company
The UK’s GlaxoSmithKline has agreed to buy US oncology company Tesaro for $5.1bn, as 'long overdue' consolidation in the pharmaceutical sector continues apace.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts